NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today welcomed the announcement that the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH) has been acknowledged by the UK Government as one of only seven Accelerated Access Collaborative “Rapid Uptake Products.”
The UroLift System will now benefit from support from the Accelerated Access Collaborative to rapidly increase its uptake in the NHS. This enables transformative products to reach patients as quickly as possible through streamlined regulatory and market access decisions.
Neil Barber, Consultant Urologist, Frimley Health NHS Foundation Trust, was the first surgeon to routinely offer the UroLift System on the NHS. Mr. Barber said, “I am very pleased by this news. Having been involved in the initial European randomized clinical trial, the potential benefits of the UroLift System to both patients and the NHS quickly became very clear. What was evident from the beginning was that this is an effective day case procedure that, for the first time, preserves sexual function; we could offer most patients the likely prospect going home catheter-free; and they would experience a rapid improvement in symptoms and a return to normal activity with days rather than weeks as is the case for more standard surgical options.
“What we have learned in the NHS setting since the first procedures in 2014 is that the UroLift System has hugely helped us to improve the use of our resources. In my own Trust, we have been able to relocate the site of operation from the classical operating theatre to a procedure or minor ops room, and we are able to perform up to six UroLift System procedures on one list. This helps us to release precious capacity and reduce waiting times in other parts of our service.”
Teleflex Interventional Urology EMEA Vice President and General Manager, Justin Hall, said: “We are humbled and honored to hear that the UroLift System is one of the seven products that Accelerated Access Collaborative has chosen to support, enabling rapid increase in their uptake.
The inclusion of the UroLift System into the Accelerated Access Collaborative Rapid Uptake Products list follows the decision by NHS England in 2017 to name the treatment as one of the first recipients of the first Innovation and Technology Tariff, which essentially helped to fast track this minimally invasive, day case treatment into the NHS.
Mr. Hall added, “Today’s announcement shows that the Government acknowledges the treatment’s unique clinical benefits and our quality of robust clinical evidence, and increasingly, real world data, gathered from NHS urologists. Their experience shows that using the UroLift System allows them to deliver benefits for NHS urology departments: in terms of reducing overall costs and complications; saving substantial numbers of bed days; and hours of operating theatre time. The UroLift System potentially frees capacity for urologists to focus on critical cancer targets and waiting times, reducing delays in urgent and planned surgery.
“Our close partnership with NHS clinicians and regulators is enabling a true service transformation: not only for men and their treatment options but also in terms of developing a methodology of how to adopt a disruptive healthcare technology, such as The UroLift System, and embed it into the NHS, in a comparatively markedly shorter time than previous innovations.”
Jean-Luc Dianda, President, EMEA,Teleflex, said, “The UroLift System is a recent acquisition for Teleflex, and we believe it perfectly fits our mission statement to deliver medical technologies designed to improve the health and quality of people’s lives. Today’s announcement demonstrates that the treatment is now also additionally acknowledged as a transformative technology within a major public healthcare system.”
About the UroLift ® System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Nearly 70,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® System and Weck® – trusted brands united by a common sense of purpose.
Neil Barber is a paid consultant to NeoTract | Teleflex Interventional Urology.
MAC00884-01 Rev A
For Teleflex Incorporated:
Jake Elguicze, 001 610.948.2836
Treasurer and Vice President, Investor Relations
Gloucester Road Communications
Amanda Hayhurst, 0044 772 0205581
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Airspan Introduces 5G Millimeter Wave RAN Infrastructure Utilizing the Qualcomm FSM100xx 5G Platform19.2.2019 16:36:00 | Tiedote
Airspan Networks Inc. is excited to announce today that they will be expanding their cooperation with Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, to include the development of 5G NR mmWave RAN solutions, leveraging the Qualcomm FSM100xx 5G Platform. This comes in the wake of the joint multi-award-winning success in 4G for the Sprint Magic Box and Reliance Jio’s ground-breaking ultra-dense Greenfield network. Airspan has deployed close to half a million small cells worldwide based on the powerful Qualcomm FSM99xx Small Cell Platform, leveraging its advanced feature sets. Airspan has been able to deliver on the promise of 4G small cells to improve indoor and outdoor wireless network capacity and coverage, increasing macro network efficiency and revolutionizing TCO. Airspan is developing 5G RAN solutions, in both Sub-6 GHz and mmWave bands to meet the wide range of challenges experienced today by mobile operators. The products will feature advanced technologies inc
Sartorius Closes Fiscal 2018 Successfully and Aims to Further Expand19.2.2019 16:08:00 | Tiedote
Sartorius (FWB:SRT), a leading international partner of biopharmaceutical research and the industry, confirmed its preliminary figures with the publication of its 2018 Annual Report. Accordingly, the Group continued on the growth track in both divisions and across all geographies, and thus achieved its forecast raised considerably at mid-year. Group sales revenue rose in constant currencies by 13.2% to 1,566.0 million euros (reported: +11.5%), with the non-organic share of this figure amounting to around one percentage point. The EMEA region (Europe | Middle East | Africa) accounted for 42% of consolidated sales; the Americas, 33%; and Asia | Pacific, 25%. Order intake rose in constant currencies by 12.5% to 1,662.5 million euros. The positive development of the Group is reflected by the organic increase in the number of employees. As at December 31, 2018, a total of 8,125 people were employed at Sartorius worldwide; this was a year-over-year gain of some 600 new employees or 8.3%. “Sa
BOC Group Announces the Release of its Latest BPM Suite: ADONIS NP 6.0 Out Now and Better Than Ever Before!19.2.2019 16:00:00 | Tiedote
BOC Group has just released the next major version upgrade of its BPM suite ADONIS NP and introduced a great mix of brand new features, enhanced extensions and different technology updates. The new ADONIS NP 6.0 brings meaningful innovation for all users, with a special emphasis on making better decisions faster with the help of Business Process Simulation & Optimization. Providing powerful Process Simulation, the latest release of the Business Transformation Suite ADONIS NP encompasses major new features and cutting-edge capabilities to facilitate, optimize and accelerate digital transformation! It is a step forward into a new era of innovation and simplicity. Tobias Rausch, ADONIS NP product manager says: “Business Process Simulation & Optimization is without a doubt the flagship feature of the new ADONIS NP 6.0. It allows you to visualize, change, slice and dice your processes and test alternatives in a risk-free environment, before taking an actual step change and committing capita
The Company SP3H Announces It Has Entered the Final Phase of Its European VIP Program (Intelligent and Clean Vehicle), Linked to the Pre-Industrialization of Its fluidBOX Infrared Scanners19.2.2019 14:05:00 | Tiedote
The first orders have already been posted on the car market, in anticipation of the introduction of the new EU legislation on CO 2 emissions target from vehicles in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190219005456/en/ This success has enabled SP3H to receive the second tranche of € 473k from the EU, thus raising the amount received since October 2017 to € 1M. During the summer of 2017, VIP received the prestigious H2020 label "EIC SME Instrument Phase 2" in the "transport & smart cities mobility" category. With a total budget of 1.7M €, VIP is subsidized by the European Union for 70% or 1.2M€ has enabled SP3H to join the prestigious circle of French winners of the H2020 EIC SME Instrument Phase 1 and 2 programs. VIP is the pre-industrialization program for Fluidbox sensors, the first miniaturized scanner in the world capable of analyzing the quality of fuels in vehicles. The heart of the program remains clos
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study19.2.2019 14:00:00 | Tiedote
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, disclosed today positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190219005354/en/ Figure 1A & 1B The clinical study demonstrated that patients implanted with the Axonics r-SNM System received clinically meaningful and statistically significant improvements in Urinary Urgency Incontinence (“UUI”) symptoms and quality of life. Additionally, the study met all secondary endpoints. No serious device-related adverse events have been reported. The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center,
H.I.G. Capital Closes H.I.G. Europe Real Estate Fund Well Above Target19.2.2019 14:00:00 | Tiedote
H.I.G. Capital (“H.I.G.”), a leading global alternative asset management firm with over $30 billion of equity capital under management, is pleased to announce the closing of H.I.G. Europe Realty Partners II (the “Fund”). The Fund closed with aggregate capital commitments of €673 million* ($760 million), well above its target. The Fund will principally make value-add investments in the small and mid-cap real estate sector in Europe. Sami Mnaymneh and Tony Tamer, Co-CEOs of H.I.G., commented: “We are delighted with the success of H.I.G. Europe Realty Partners II. The Fund will continue to build on our local, on the ground pan-European presence and is already 16% committed. We continue to find compelling opportunities to invest in the region.” Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “This closing validates H.I.G. Europe Realty's differentiated strategy. The Fund will invest in Europe across the capital structure and asset classes with a p
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme